Araştırma Çıktıları

Permanent URI for this communityhttps://hdl.handle.net/11443/931

Browse

Subject: search.filters.subject.metabolic syndrome

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Impact of metabolic syndrome on pre- and postoperative parameters in patients undergoing a HoLEP surgery
    (AVES, 2019-01-01) Aydogan, Tahsin Batuhan; Kaya, Engin; Gazel, Eymen; Yalcin, Serdar; Aybal, Halil Cagri; Tunc, Lutfi
    Objective: We aimed to investigate the safety and success of the holmium laser enucleation of prostate (HoLEP) surgery in patients with metabolic syndrome (MS) versus those without MS who have similar prostate sizes. Material and methods: Data from 120 patients who underwent HoLEP by a single surgeon between November 2015 and January 2018 were prospectively analyzed. Group 1 (n=40) and Group 2 (n=80) consisted of patients with and without MS, respectively. Preoperative-and postoperative third month control variables that were compared between the groups included hemoglobin (Hb) level
  • Thumbnail Image
    Item
    Effects of Regular Kefir Consumption on Gut Microbiota in Patients with Metabolic Syndrome: A Parallel-Group, Randomized, Controlled Study
    (MDPI, 2019-01-01) Bellikci-Koyu, Ezgi; Sarer-Yurekli, Banu Pinar; Akyon, Yakut; Aydin-Kose, Fadime; Karagozlu, Cem; Ozgen, Ahmet Gokhan; Brinkmann, Annika; Nitsche, Andreas; Ergunay, Koray; Yilmaz, Engin; Buyuktuncer, Zehra
    Several health-promoting effects of kefir have been suggested, however, there is limited evidence for its potential effect on gut microbiota in metabolic syndrome This study aimed to investigate the effects of regular kefir consumption on gut microbiota composition, and their relation with the components of metabolic syndrome. In a parallel-group, randomized, controlled clinical trial setting, patients with metabolic syndrome were randomized to receive 180 mL/day kefir (n = 12) or unfermented milk (n = 10) for 12 weeks. Anthropometrical measurements, blood samples, blood pressure measurements, and fecal samples were taken at the beginning and end of the study. Fasting insulin, HOMA-IR, TNF-alpha, IFN-gamma, and systolic and diastolic blood pressure showed a significant decrease by the intervention of kefir (p <= 0.05, for each). However, no significant difference was obtained between the kefir and unfermented milk groups (p > 0.05 for each). Gut microbiota analysis showed that regular kefir consumption resulted in a significant increase only in the relative abundance of Actinobacteria (p = 0.023). No significant change in the relative abundance of Bacteroidetes, Proteobacteria or Verrucomicrobia by kefir consumption was obtained. Furthermore, the changes in the relative abundance of sub-phylum bacterial populations did not differ significantly between the groups (p > 0.05, for each). Kefir supplementation had favorable effects on some of the metabolic syndrome parameters, however, further investigation is needed to understand its effect on gut microbiota composition.
  • No Thumbnail Available
    Item
    Low serum 25(OH)D levels are associated to higher BMI and metabolic syndrome parameters in adult subjects in Turkey
    (MAKERERE UNIV, FAC MED, 2015-01-01) Tosunbayraktar, Guler; Bas, Murat; Kut, Altug; Buyukkaragoz, Aylin Hasbay
    Background: The aim of this study was to investigate the association of 25(OH) D levels with biochemical, anthropometric, and metabolic data obtained from normal and obese people. Methods: This study was carried out on 90 individuals between the ages of 18 to 63 that had various body mass indexes. Blood samples and anthropometric measurements were taken. Results: Waist circumferences, fat mass, LDL cholesterol levels, HDL cholesterol levels, 25(OH) D levels, and triglyceride levels were significantly different according to the body mass index groups of the participants (p<0.05). When compared to the normal body mass index group, both other groups (overweight and obese) had higher waist circumferences, triglyceride levels, LDL cholesterol levels, fasting insulin levels, HOMA-IR ratios, parathyroid hormone levels, and fat mass, and had lower 25(OH) D levels (p<0.05). The overweight group participants had higher 25(OH) D levels than the obese group, and had lower waist circumferences, fat mass, fasting insulin level, HOMA-IR ratios, and HbA1C and PTH levels than those in the obese group (p<0.05). Conclusion: In conclusion, the mean level of 25(OH) D is very low in overweight and obese individuals and low serum 25(OH) D levels appear to be associated with obesity, visceral obesity, hypertriglyceridemia, insulin resistance, and metabolic syndrome in obese patients.
  • Thumbnail Image
    Item
    An overview of polycystic ovary syndrome in aging women
    (GALENOS YAYINCILIK, 2021-01-01) Celik, Ozlem; Kose, Mehmet Faruk
    The manifestations of polycystic ovary syndrome (PCOS), a ubiquitous reproductive disorder, may vary significantly depending on the severity of a number of endocrine and metabolic changes. Although no diagnostic criteria are presently available for PCOS for perimenopausal and menopausal women, the condition can still be suspected in case of a previous diagnosis of the condition, a chronic history of irregular menstrual cycles and hyperandrogenism, and/or polycystic ovarian morphology during the reproductive period. PCOS is associated with long-term health risks, including obesity, diabetes, hypertension, dyslipidemia, metabolic syndrome and cardiovascular risk factors during reproductive age, especially in patients possessing classic phenotypes. The aim of this review was to outline the available data about the impact of PCOS on long-term health risks after reproductive age in patients with PCOS. Previously, it was assumed that women with PCOS would be more prone to develop cardiometabolic diseases after reproductive age but current data suggest that in accordance with the healing in the phenotypic characteristics of PCOS, no deterioration appears to occur in cardiometabolic health in these patients. While there is substantial evidence for a greater prevalence of abnormal subclinical atherosclerotic markers among younger patients with PCOS, data for older women are insufficient. However, there is also support for an increased risk of endometrial cancer in PCOS patients. Extensive prospective cohort studies in which healthy controls as well as patients with defining PCOS phenotypes are observed and monitored from the early reproductive period into the late postmenopausal period should now be performed in order to clarify morbidities and mortality in aging women with PCOS.